Aerosolised ciclosporin

Drug Profile

Aerosolised ciclosporin

Alternative Names: Cyclosporine aerosol; Cyclosporine inhalation solution; Pulminiq

Latest Information Update: 27 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer APT Pharmaceuticals Inc
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lung transplant rejection
  • New Molecular Entity No

Highest Development Phases

  • No development reported Lung transplant rejection

Most Recent Events

  • 27 Jul 2015 No recent reports on development identified - Phase-III for Lung transplant rejection (Prevention) in USA and Canada (Inhalation)
  • 30 Sep 2008 Phase-III clinical trials in Lung transplant rejection in Canada (Inhalation)
  • 30 Sep 2008 APT Pharmaceuticals initiates enrolment in a phase III trial for Lung transplant rejection in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top